"The Manning & Napier World Opportunities fund-rated five stars by Morningstar and ranked in the top one percentile for the past 10-year stretch-is a large-cap foreign blend fund that invests mainly in developed countries, particularly in Western Europe; thus its increasingly hefty stake in the relatively small Chinese technology company Mindray Medical International (MR), one of just two Chinese stocks it owns, is striking," suggests Stephen Leeb.

The editor of The Complete Investor explains, "The fund began accumulating Mindray shares in 2009's second quarter; as of November it owned 2.5 million shares, representing a 1.6 % weighting.

This post is part of a 12-article feature on the best bets for investing in China. To see all the other recommendations in this special report, click here.

"Shanghai-based Wuxi PharmaTech (NYSE: WX), a new addition to our model portfolio, is a bargain," says China region expert Jim Trippon.

In his The China Stock Digest, he explains, "In a nutshell, WuXi performs pharmaceutical R&D on a contract basis for paying clients; it provides services to nine of the top ten pharmaceutical companies in the world."

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"China Sky One Medical (NASDAQ: CSKI) -- which manufactures pharmaceutical, medicinal and diagnostic products -- is our top pick for 2009," says Benson George in The Growth Report.

"China Sky One has delivered solid results -- for the nine months ended September 30, 2008, revenues increased to $65.9 million, up 80% from $36.6 million in the year-ago period.

"Net income over this period was $21.9 million or $1.39 per diluted share, up from $11.2 million, or $0.90 per diluted share in the nine months ended September 30, 2007.

"Despite the economic downturn, China Sky continues to see strong demand and growth both organically and by way of acquisition.

"On Nov. 9, the company increased its 2008 revenue guidance by almost 10% to the $88 to $90 million range, representing more than an 80% increase from 2007.

"The company is highly profitable, and cash flow from operations added almost $27 million to its coffers for the first nine months of 2008.